Intravenous enoxaparin anticoagulation in percutaneous left atrial cardiac procedures

EuroIntervention 2017;13:1226-1233 published online August 2017. DOI: 10.4244/EIJ-D-17-00518

Paul Guedeney
Paul Guedeney1, MD; Nadjib Hammoudi1, MD, PhD; Guillaume Duthoit1, MD; Yan Yan1,2, MD; Johanne Silvain1, MD, PhD; Françoise Pousset1, MD; Richard Isnard1, MD; Alban Redheuil3, MD, PhD; Mathieu Kerneis1, MD; Jean-Philippe Collet1, MD, PhD; Gilles Montalescot1*, MD, PhD; for the ACTION Study Group
1. Sorbonne Université Paris 6, ACTION study group, Institut de Cardiologie (AP-HP), INSERM UMRS 1166, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France; 2. Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical Unive

Aims: Percutaneous transcatheter device closure of left atrial appendage (LAA), patent foramen ovale (PFO) and atrial septal defect (ASD) are usually performed with unfractionated heparin

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

adjunctive pharmacotherapyantithrombotic treatmentatrial septal defectleft atrial appendage closurepatent foramen ovale closure
Read next article
3D printing for sizing left atrial appendage closure device: head-to-head comparison with computed tomography and transoesophageal echocardiography

Latest news